Bempedoic Acid

Why This Matters

For many patients, statins alone do not achieve adequate lowering of LDL cholesterol or ApoB, while others are unable to tolerate statin therapy because of muscle-related symptoms. Bempedoic acid offers an important additional treatment option. Although it lowers cholesterol synthesis, its greatest clinical benefit — like that of statins — results from increasing hepatic LDL receptor activity and enhancing the clearance of ApoB-containing lipoproteins.

What Is Bempedoic Acid?

Bempedoic acid is an oral lipid-lowering medication that inhibits ATP-citrate lyase (ACL), an enzyme that functions upstream of HMG-CoA reductase in the same mevalonate pathway described in Chapter 23 — one step earlier in the trunk that statins act on further downstream.

By reducing hepatic cholesterol synthesis, bempedoic acid lowers intracellular cholesterol concentrations within hepatocytes. The liver responds by increasing LDL receptor expression, thereby removing more ApoB-containing lipoproteins from the circulation.

How Bempedoic Acid Works

Bempedoic acid is an inactive prodrug that becomes active only after conversion by very long-chain acyl-CoA synthetase-1 (ACSVL1), an enzyme expressed in the liver.

Because skeletal muscle lacks this activating enzyme, the drug never reaches meaningful active concentrations in muscle tissue. This liver-specific activation is the key mechanistic difference from statins and explains bempedoic acid's markedly lower rate of muscle-related adverse effects.

Once activated in the liver, inhibition of ACL reduces cholesterol synthesis, activates sterol regulatory element-binding proteins (SREBPs), increases hepatic LDL receptor expression, and enhances clearance of circulating ApoB-containing lipoproteins.

Lipid Effects

Bempedoic acid lowers LDL cholesterol by roughly 18 to 25% as monotherapy, and produces modest reductions in ApoB, non-HDL cholesterol, and high-sensitivity C-reactive protein (hs-CRP).

When combined with ezetimibe or statins, LDL lowering is additive because each therapy acts at a different point within cholesterol homeostasis. The reduction in ApoB-containing particle number is believed to account for most of its cardiovascular benefit.

Clinical Benefits

The CLEAR Outcomes trial demonstrated that bempedoic acid lowers the risk of major adverse cardiovascular events in statin-intolerant patients at elevated cardiovascular risk.

Its benefit is particularly relevant for individuals who are unable to tolerate recommended statin doses or who require additional LDL reduction despite maximally tolerated lipid-lowering therapy. As with other lipid-lowering agents, cardiovascular benefit parallels the reduction in lifetime exposure to ApoB-containing lipoproteins.

Safety and Adverse Effects

Bempedoic acid is generally well tolerated.

Because of its liver-specific activation, muscle-related adverse effects occur less frequently than with statins. However, the drug may increase serum uric acid levels and has been associated with an increased risk of gout in susceptible individuals. Small increases in serum creatinine, hepatic enzymes, and rare cases of tendon injury have also been reported, and these potential adverse effects should be weighed when selecting therapy.

Bempedoic acid is sometimes described as sparing coenzyme Q10, one of the other products of the mevalonate pathway, because its point of inhibition sits above the branch that produces CoQ10 rather than below it as with statins. This is mechanistically plausible but remains an unproven, not disproven, claim — it has not been established as a clinically meaningful advantage and should not be overstated.

Clinical Relevance

Bempedoic acid provides a genuine option for the sizable group of patients who cannot reach their LDL or ApoB targets with statins alone, either because of intolerance or because maximally tolerated statin therapy is not enough. It is often used in combination with ezetimibe, and increasingly as part of a broader regimen that may also include PCSK9 inhibitors or ANGPTL3 inhibitors in higher-risk patients, covered in the next chapter.

Clinical Pearls

• Bempedoic acid inhibits ATP-citrate lyase, one step upstream of the statin target in the mevalonate pathway.
• It is a prodrug activated only in the liver, which is why it largely spares skeletal muscle.
• Monotherapy LDL reduction is roughly 18-25%, additive with ezetimibe or statins.
• CLEAR Outcomes confirmed cardiovascular event reduction in statin-intolerant patients.
• Uric acid elevation and gout risk are real caveats; CoQ10-sparing is a plausible but unproven claim.

Common Misconceptions

Misconception: Bempedoic acid works the same way statins do.

Reality: It inhibits a different enzyme, one step upstream of HMG-CoA reductase, and its liver-specific activation is what distinguishes its side-effect profile from that of statins.

Misconception: Bempedoic acid is proven to protect against the muscle and CoQ10 effects sometimes attributed to statins.

Reality: The liver-specific activation mechanism plausibly explains lower rates of muscle symptoms, and this has been confirmed clinically; the CoQ10-sparing claim specifically remains theoretical and should be described as such.

Misconception: Bempedoic acid has no meaningful downsides.

Reality: It carries its own caveats, particularly a real risk of raising uric acid and precipitating gout in susceptible patients.

Clinical Bottom Line

Bempedoic acid lowers ApoB-containing lipoproteins by inhibiting cholesterol synthesis one step upstream of the statin target, and its liver-specific activation explains why it largely avoids the muscle-related side effects that limit statin use in some patients. It is not a replacement for statins in patients who tolerate them, but it is a genuine and evidence-backed option for those who do not.